Literature DB >> 26819003

Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion.

Romy M W Kremers1, Rob J Wagenvoord, H Bas de Laat, Paul Monagle, H Coenraad Hemker, Vera Ignjatovic.   

Abstract

Thrombin generation (TG) is decreased in children. TG is determined by two underlying processes: the conversion of prothrombin to thrombin and the inactivation of thrombin. Therefore, lower TG capacity in children can either be caused by a reduction of prothrombin conversion, an increase of thrombin inactivation, or both. In 36 children and 8 adults, TG and the factors that determine thrombin inactivation (antithrombin, α2Macroglobulin (α2M) and fibrinogen) were measured. Prothrombin conversion, thrombin inhibitor complex formation, and the overall thrombin decay capacity were determined. In silico modelling was performed to determine the contribution prothrombin conversion and thrombin inactivation to deviant paediatric TG. Both the amount of prothrombin converted and the maximal prothrombin conversion rate are significantly reduced in children as compared to adults. This is partly due to the prothrombin levels being lower and partly to a lower prothrombin conversion rate. The overall thrombin decay capacity is not significantly different in children, but α2Macroglobulin plays a more important role than it does in adults. In silico experiments demonstrate that reduced prothrombin conversion and to a lesser extent elevated α2M levels provide an explanation for low TG in children. Young age has a dual effect on prothrombin conversion. Lower plasma prothrombin levels result in decreased prothrombin conversion but the rate of prothrombin conversion is also decreased, i. e. the development of prothrombinase is lower than in adults.

Entities:  

Keywords:  Developmental haemostasis; haemostatic balance; prothrombin conversion; thrombin generation; thrombin inactivation

Mesh:

Substances:

Year:  2016        PMID: 26819003     DOI: 10.1160/TH15-09-0716

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Authors:  Romy M W Kremers; Stéphane Zuily; Hilde Kelchtermans; Tessa C Peters; Saartje Bloemen; Véronique Regnault; H Coenraad Hemker; Philip G de Groot; Denis Wahl; Bas de Laat
Journal:  Blood Adv       Date:  2018-06-12

2.  Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.

Authors:  Romy M W Kremers; Marie-Claire Kleinegris; Marisa Ninivaggi; Bas de Laat; Hugo Ten Cate; Ger H Koek; Rob J Wagenvoord; H Coenraad Hemker
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

3.  Deciphering the coagulation profile through the dynamics of thrombin activity.

Authors:  Romy M W de Laat-Kremers; Qiuting Yan; Marisa Ninivaggi; Moniek de Maat; Bas de Laat
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

4.  Mathematical modelling indicates that lower activity of the haemostatic system in neonates is primarily due to lower prothrombin concentration.

Authors:  Ivo Siekmann; Stefan Bjelosevic; Kerry Landman; Paul Monagle; Vera Ignjatovic; Edmund J Crampin
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

5.  Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay.

Authors:  Audrey Carlo; Qiuting Yan; Hugo Ten Cate; Romy De Laat-Kremers; Bas De Laat; Marisa Ninivaggi
Journal:  Front Cardiovasc Med       Date:  2022-07-26

6.  Neonatal Platelets: Lower G12/13 Expression Contributes to Reduced Secretion of Dense Granules.

Authors:  Axel Schlagenhauf; Sheila Bohler; Mirjam Kunze; Tanja Strini; Harald Haidl; Miriam Erlacher; Barbara Zieger
Journal:  Cells       Date:  2022-08-17       Impact factor: 7.666

7.  Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.

Authors:  E Vincent S Faustino; Leslie J Raffini; Sheila J Hanson; Jill M Cholette; Matthew G Pinto; Simon Li; Sarah B Kandil; Marianne E Nellis; Veronika Shabanova; Cicero T Silva; Joana A Tala; Tara McPartland; Philip C Spinella
Journal:  Crit Care Med       Date:  2021-04-01       Impact factor: 9.296

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.